Oxford Biomedica (LON:OXB – Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%.
Oxford Biomedica Stock Performance
Shares of LON:OXB traded down GBX 10 during trading on Wednesday, reaching GBX 483. The company had a trading volume of 650,515 shares, compared to its average volume of 1,106,726. Oxford Biomedica has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 952. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The stock’s fifty day moving average price is GBX 515.68 and its 200 day moving average price is GBX 577.12. The firm has a market capitalization of £584.66 million, a price-to-earnings ratio of -17.94 and a beta of 1.09.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 595 target price on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Finally, Royal Bank Of Canada restated an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.
Key Headlines Impacting Oxford Biomedica
Here are the key news stories impacting Oxford Biomedica this week:
- Positive Sentiment: Improving client pipeline: OXB’s outlook was maintained as its client pipeline improved revenue visibility. The company has also secured 17 new clients, supporting expectations for future growth. OXB outlook maintained as client pipeline improves revenue visibility OXB wins 17 new clients as its expansion gathers pace
- Positive Sentiment: Revenue growth and guidance maintained: First-half revenue rose 9% to £80.2 million, while management reiterated its full-year 2026 sales outlook. Record commercial wins indicate continued demand for OXB’s cell and gene therapy manufacturing services. Oxford Biomedica delivers solid H1 growth, record commercial wins
- Neutral Sentiment: Quality systems investment: Oxford Biomedica is advancing a global quality transformation using Veeva Quality Cloud. The initiative may improve consistency and scalability, although it is primarily an operational development rather than an immediate earnings catalyst. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
- Negative Sentiment: Losses remain the key concern: OXB reported quarterly earnings of negative 30.39 pence per share, alongside a negative net margin and return on equity. The half-year loss widened even as revenue increased, highlighting ongoing profitability and execution risks. Oxford Biomedica reiterates sales outlook but half-year loss widens
Oxford Biomedica Company Profile
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Featured Articles
- Five stocks we like better than Oxford Biomedica
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
